MD Anderson Remains Top-Ranked Cancer Center

U.S. News &World Report named University of Texas MD Anderson Cancer Center in Houston as the No. 1 Adult Cancer Hospital in America for the fifth consecutive year. Memorial Sloan-Kettering Cancer Center in New York, Mayo Clinic in Rochester, Minnesota, Johns Hopkins Hospital in Baltimore and Dana-Farber/Brigham and Women’s Cancer Center in Boston, round out the top five, respectively. All five have highly regarded specialty centers for pleural mesothelioma, the rare and aggressive cancer caused by the inhalation of asbestos fibers. The expertise in mesothelioma treatment contributed to the top rankings in the 2019-20 Best Hospitals for Cancer category. “Mesothelioma is a challenging condition to treat. And these [high-ranking] hospitals specialize in treating complex cancers,” said Ben Harder, managing editor and chief of Health Analysis at U.S. News &World Report. “The more experience a doctor or hospital has with a particular diagnosis, the better the outcomes tend to be. That’s why we evaluate hospitals.” Rankings Help Guide Patients The cancer rankings are part of a broader Best Hospitals Honor Roll done annually by U.S. News &World Report. Overall rankings involve 16 areas of complex specialty care, which includes cancer, cardiology and heart surgery, gynecology, orthopedics and urology. The rankings are designed to provide assistance to patients making decisions about the best places to receive their care. Mesothelioma pa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractActivated cap-dependent translation promotes cancer by stimulating translation of mRNAs encoding malignancy-promoting proteins. The nucleoside monophosphate Protide, 4Ei-10, undergoes intracellular uptake and conversion by Hint1 to form 7-Cl-Ph-Ethyl-GMP. 7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap. The effects of inhibiting translation initiation by disruption of the eIF4F complex with 4Ei-10 were examined in malignant mesothelioma (MM). In a cell-free assay system, formation of the eIF4F complex was disab...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, we comprehensively analyzed the expression profile and prognostic value of HOXC11 in human pan-cancer using online The Cancer Genome Atlas (TCGA) databases. HOXC11 was widely up-regulated in tumor tissues when compared with the normal tissues in pan-cancer across nine cancer types. In addition, high mRNA level of HOXC11 predicted poor overall survival (OS) of patients with adrenocortical carcinoma (ACC), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), mesothelioma (MESO) and pancreatic adenocarcinoma (PAAD), respectively. By comparative analysis, we found that HOXC11 was up-regulated a...
Source: Life Sciences - Category: Biology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Environmental Health | Heart | Hospitals | Mesothelioma | Nurses | Nursing | Orthopaedics | Texas University | Urology & Nephrology | Women